We are pleased to announce the release of our new and unique probe ZytoLight SPEC 11q gain/loss Triple Color Probe (Z-2216-50), designed to detect 11q alteration characterized by proximal gains and telomeric losses in Burkitt-like lymphomas.
This subset of lymphomas with gene expression and pathological characteristics of Burkitt lymphomas (BL) but absence of MYC translocation has been recently described. Compared with BL, these lymphomas have more complex karyotypes, lower levels of MYC expression, a certain degree of cytological pleomorphism, occasionally a follicular pattern, and frequently a nodal presentation. The clinical course seems to be similar to BL, but the number of cases reported is still limited. Although more studies are needed, the consensus for the revised WHO classification was to consider these a new provisional entity designated Burkitt-like lymphoma with 11q aberration.
This new entity/category is defined in the 2016 revision of the WHO Classification of Lymphoid Neoplasms (Swerdlow et al., 2016). Our probe is to the best of our knowledge the first commercially available CE IVD probe to detect this subgroup of Burkitt lymphoma.